Mouse Anti-GD2 Recombinant Antibody (clone 3G6) (CAT#: NS-030CN)

Figure 1 Flow cytometry of control-transfected and mouse CD59-transfected EL4 cells.

EL4 lymphoma cells were transfected with mouse CD59 or empty vector and a homogenous population of CD59-expressing cells was isolated by cell sorting. Expression of the complement regulatory proteins and GD2 on EL4/vector and EL4/mCD59 transfectants. Expression of GD2 was detected by mouse anti-GD2 mAb 14G2a (IgG2a) and 3G6 (IgM). Representative analysis.

Imai, M., Landen, C., Ohta, R., Cheung, N. K. V., & Tomlinson, S. (2005). Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer research, 65(22), 10562-10568.

Figure 2 The complement sensitivity of mouse CD59-and vector-transfected EL4 cells.

C3 deposition (A) was detected by flow cytometry and complement lysis, or CMC (B) was determined by 51Cr release assay. Experiments were done in the presence of 30% fresh mouse serum and various antibodies: 14G2a, anti-GD2 IgG; 3G6, anti-GD2 IgM; 5D5 [F(ab′)2], anti-mouse Crry; 3B3, anti-mouse CD59. Effect of anti-GD2 antibodies alone on cell proliferation (C) was assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay. Columns, mean (n = 4-7 for all experiments); bars, SD.

Imai, M., Landen, C., Ohta, R., Cheung, N. K. V., & Tomlinson, S. (2005). Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer research, 65(22), 10562-10568.

Figure 3 Effect of anti-GD2 IgM therapy on survival and metastasis after challenge with EL4 cells.

A, survival curve. Mice were injected i.v. with 3 × 10⁴ EL4 cells and indicated amount of anti-GD2 IgM (3G6) or IgG (14G2a). Antibody injections were on day 2 following challenge or on days 1 and 2 for IgM. B, number of metastatic tumor nodules on day 23 after challenge counted in liver of mice treated with PBS, 14G2a (100 Mg on day 2) or 3G6 (200 Mg on days 1 and 2); n = 5-8. C, representative livers from antibody treated mice (as in B) at day 23 after challenge. D, liver weight of PBS and antibody treated mice (as in B) at day 23 after challenge (n = 5-8). *, P < 0.05.

Imai, M., Landen, C., Ohta, R., Cheung, N. K. V., & Tomlinson, S. (2005). Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer research, 65(22), 10562-10568.

Figure 4 Effect of anti-GD2 therapy in mice challenged with mouse CD59-transfected EL4 cells.

A, survival curve. Mice were injected i.v. with 3 × 10⁴ EL4 cells and anti-GD2 IgM (3G6, 200 Mg on days 1 and 2 after challenge). B, number of metastatic tumor nodules on livers from antibody treated mice at day 23 after challenge (n = 8). C, liver weight livers from antibody treated mice at day 23 after challenge (n = 5). *, P < 0.05.

Imai, M., Landen, C., Ohta, R., Cheung, N. K. V., & Tomlinson, S. (2005). Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer research, 65(22), 10562-10568.

Figure 5 Effect of anti-GD2 therapy in C3-deficient mice challenged with EL4 cells.

A, survival curve. Mice were injected i.v. with 3 × 10⁴ EL4 cells and with PBS or 3G6 anti-GD2 IgM (200 Mg on days 1 and 2) after challenge (n = 7). B, number of metastatic tumor nodules on livers from antibody treated mice at day 23 after challenge (n = 8). C, liver weight livers from antibody treated mice at day 23 after challenge (n = 5).

Imai, M., Landen, C., Ohta, R., Cheung, N. K. V., & Tomlinson, S. (2005). Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer research, 65(22), 10562-10568.